Results 91 to 100 of about 1,090 (155)

Evolution of drug-binding residues in bacterial ribosomes

Ekemezie CL, Chan LI, Brown CR, Helena-Bueno K, Williams TA, Melnikov SV.   +5 more
europepmc   +1 more source

Six-Year Prescription Pattern of Antimicrobial Use in Cats at the Veterinary Teaching Hospital of the University of Pisa. [PDF]

Animals (Basel)
De Marchi L, Vernaccini M, Meucci V, Briganti A, Lippi I, Marchetti V, Intorre L.   +6 more
europepmc   +1 more source

Molecular typing and antimicrobial susceptibility profiles of Campylobacter jejuni and Campylobacter coli Isolates from Patients and raw meat in Huzhou, China, 2021-2022. [PDF]

PLoS One
Wu X, Liping C, Dong F, Yan W, Shen Y, Ji L.   +5 more
europepmc   +1 more source

Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses.

Lancet Microbe
Melchiorri D, Rocke T, Alm RA, Cameron AM, Gigante V.   +4 more
europepmc   +1 more source

<i>In vitro</i> antimicrobial susceptibility of <i>Mycoplasma pneumoniae</i> isolates across different regions of China in 2023. [PDF]

JAC Antimicrob Resist
Yan C, Chen Y, Ren X, Jia X, Du B, Zhao H, Feng Y, Xue G, Cui J, Liu X, Yuan J.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The Ketolides

Drugs, 2002
Ketolides are a new class of macrolides designed particularly to combat respiratory tract pathogens that have acquired resistance to macrolides. The ketolides are semi-synthetic derivatives of the 14-membered macrolide erythromycin A, and retain the erythromycin macrolactone ring structure as well as the D-desosamine sugar attached at position 5.
George G, Zhanel, Michael, Walters, Ayman, Noreddin, Lavern M, Vercaigne, Aleksandra, Wierzbowski, John M, Embil, Alfred S, Gin, Stephen, Douthwaite, Daryl J, Hoban   +8 more
openaire   +4 more sources

Ketolides in the Treatment of Respiratory Infections

Expert Opinion on Pharmacotherapy, 2002
The ketolides are a new class of macrolides specifically designed to combat respiratory tract pathogens that have acquired resistance to macrolides. The ketolides are semi-synthetic derivatives of the 14-membered macrolide erythromycin A. There are currently two ketolides in the late stages of clinical development in the US (telithromycin [HMR-364 ...
George G Zhanel, Daryl J Hoban
exaly   +3 more sources

Recent Developments on Ketolides and Macrolides.

Current Medicinal Chemistry, 2001
Recent semi-synthetic studies of erythromycin A culminated in the discovery of two ketolide drug candidates, HMR-3647 and ABT-773, for the treatment of community-acquired bacterial infections caused by both macrolide- and beta-lactam-susceptible and -resistant S. pneumoniae, gram negative bacteria, and intracellular atypical pathogens. The discovery of
Yong-Jin Wu
exaly   +3 more sources

Resistance to Ketolide Antibiotics by Coordinated Expression of rRNA Methyltransferases in a Bacterial Producer of Natural Ketolides [PDF]

Proceedings of the National Academy of Sciences of the United States of America, 2015
Significance Studies of antibiotic resistance are usually initiated in earnest only after resistance has become established in clinical pathogens. Here, we forewarn of a resistance mechanism to the novel antibiotics ketolides, which are only coming into broad medical practice.
Stephen Douthwaite, David H. Sherman, Alexander S Mankin   +2 more
exaly   +4 more sources

Telithromycin: The First of the Ketolides

Annals of Pharmacotherapy, 2002
OBJECTIVE: To review the chemistry, spectrum of activity, pharmacology, clinical efficacy, and safety of telithromycin. DATA SOURCES: A MEDLINE search from 1966 to December 2000 was performed via OVID and PubMed using the following ...
Christopher S, Shain, Guy W, Amsden
openaire   +2 more sources